Therapeutic Solutions International. has been granted a patent for a method to inhibit lung inflammation by co-administering T regulatory cells with umbilical cord-derived mesenchymal stem cells, enhancing their regenerative activities and reducing inflammation through a GITR-dependent mechanism. GlobalData’s report on Therapeutic Solutions International gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Therapeutic Solutions International, Cancer immunotherapy was a key innovation area identified from patents. Therapeutic Solutions International's grant share as of June 2024 was 15%. Grant share is based on the ratio of number of grants to total number of patents.
Method for reducing lung inflammation using stem cells and t regulatory cells
The granted patent US12011462B2 outlines a method for inhibiting lung inflammation, particularly in subjects suffering from conditions such as acute respiratory distress syndrome (ARDS) and lung fibrosis. The method involves identifying a subject with lung inflammation and administering a combination of T regulatory cells and plastic adherent umbilical cord-derived mesenchymal stem cells. The T regulatory cells can be derived from umbilical blood and are characterized by the expression of glucocorticoid-induced tumor necrosis factor receptor-related (GITR), with a higher expression percentage than typical T regulatory cells. The mesenchymal stem cells are specified to express various cellular markers, including CD7, CD11, CD90, and several interleukin receptors.
Additionally, the patent details that the mesenchymal stem cell population may be pretreated with an activator of indoleamine 2,3-dioxygenase, with potential activators including interferon alpha, beta, gamma, and interleukin 33. The method is particularly relevant for lung inflammation associated with COVID-19-induced ARDS. The claims emphasize the therapeutic potential of this combined cellular approach in mitigating lung inflammation, highlighting specific cellular characteristics and treatment protocols that may enhance efficacy in clinical applications.
To know more about GlobalData’s detailed insights on Therapeutic Solutions International, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
